West Virginia Senate Bill SB 1028

West Virginia 2026 Regular Session

• Introduced: 2/20/26
• Refer: 2/20/26

Caption

Relating to financial assistance available for prescription drug

Summary

SB 1028 is a bill relating to financial assistance available for prescription drugs. Based on the caption, the measure appears aimed at changing or clarifying how prescription drug assistance is provided, likely affecting programs, eligibility, or administration of aid used to help patients afford medications. Because the bill text was not available in the provided materials, the specific mechanisms, funding changes, and affected programs cannot be identified from the record here. The bill was referred to the Senate Health and Human Resources Committee on February 20, 2026, indicating it was being considered in the policy area most directly tied to public health, pharmacy access, and assistance for individuals facing high medication costs. No committee transcript or vote record was provided, so the exact scope of the proposal and any amendments are not available from the supplied context.

Impact

If enacted, SB 1028 would likely affect West Virginia statutes governing prescription drug assistance, potentially altering eligibility rules, benefit administration, or the availability of financial support for patients needing prescription medications. The bill could also have implications for state health agencies, pharmacies, insurers, and low-income or medically vulnerable residents who rely on assistance to obtain medications. The precise statutory changes cannot be determined from the available text.

Sentiment

The available record does not include committee debate, public testimony, or votes, so there is no direct evidence of support or opposition in the provided materials. The referral to Health and Human Resources suggests the bill was treated as a health-policy measure for further review, but the overall sentiment cannot be reliably characterized beyond that procedural step.

Contention

No specific points of contention are documented in the provided materials because the bill text, committee transcript, and voting history were not included. In general, legislation involving prescription drug assistance can raise questions about cost, eligibility, administrative burden, and the balance between expanding access and limiting state expenditures, but those issues are not confirmed as disputed in this bill’s record.